NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery

Danish pharmaceutical company Novo Nordisk (NVO) has teamed up with artificial intelligence (AI) leader Anthropic to leverage frontier AI models, including Claude Science, to supercharge its drug discovery and research and development (R&D) operations. 

The collaboration aims to address complex biological challenges, streamline software engineering, and compress the timelines required to bring treatments for chronic diseases to market.

The announcement arrives as Novo Nordisk stock is struggling to regain momentum, currently down about 20% versus the start of this year. 

Significance of Anthropic Partnership for NVO Stock

The strategic alliance integrates Anthropic’s advanced reasoning models into Novo’s computational labs, building directly on the latter’s broader push to build an AI-driven R&D ecosystem alongside partners like AWS. For NVO stock, the partnership represents a long-term efficiency play. 

By using AI to analyze complex biological mechanisms and accelerate lead-compound identification, Novo Nordisk seeks to lower clinical development costs and expand its pipeline beyond GLP-1 treatments.

While artificial intelligence computational tools do not yield immediate revenue, shortening drug development cycles from years to months offers structural margin protection and supports pipeline longevity.

This would help NVO maintain its competitive edge against rivals in the chronic disease market.

Should You Load Up on Novo Nordisk Shares Today?

Novo Nordisk is currently trading at a forward price-to-earnings (P/E) multiple of about 13x only, which makes it significantly cheaper to own than its key GLP-1 rival Eli Lilly (LLY) at more than 31x. 

That said, the technical setup warrants caution in playing NVO at current levels. 

Novo Nordisk shares currently sit firmly below their major moving averages (MAs), with an RSI in the early 30s indicating intense selling pressure. 

Put together with management’s recent guidance for adjusted sales to come in down 6% to flat in 2026, NVO does not look particularly appetizing for investors seeking an attractive risk-reward profile. 

What’s the Consensus Rating on Novo Nordisk?

Note that Wall Street firms aren’t super bullish on Novo Nordisk for the remainder of 2026 either.

The consensus rating on NVO shares sits at a “Hold,” with the mean price objective of about $45 indicating roughly 10% upside potential from current levels. 

On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.